The introduction of the serum Prostate-Specific Antigen (PSA) level as a biomarker for the presence of prostate cancer in 1986 prompted a progressive global increase in the diagnosis, and earlier diagnosis of the disease. The gene discussed is KLK3; the disease is prostate carcinoma.